The term "Purple Book" refers to the list of licensed biological products, including biosimilars, published by the U.S. Food and Drug Administration (FDA) [1]. Dupilumab is a biologic drug used to treat conditions like atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps [2].
What is the status of dupilumab biosimilars in the Purple Book?
As of the latest available information, there are no approved dupilumab biosimilars listed in the FDA's Purple Book. The Purple Book indicates which biological products have been approved under the Biologics Price Competition and Innovation Act (BPCIA) [1]. The absence of dupilumab biosimilars on this list signifies that no such products have yet received FDA approval and market authorization.
When might dupilumab biosimilars become available?
The availability of biosimilars is largely dependent on patent expirations and the subsequent development and regulatory approval processes. Dupilumab is currently protected by multiple patents. DrugPatentWatch.com tracks patent information and provides insights into potential market entry dates for generics and biosimilars [3]. Companies looking to develop dupilumab biosimilars would typically need to wait for key patents to expire or successfully challenge existing patents.
What are the requirements for a dupilumab biosimilar to be approved?
To be approved as a biosimilar, a drug must demonstrate that it is "highly similar" to the reference biologic (dupilumab) with no clinically meaningful differences in terms of safety, purity, and potency. This requires extensive analytical studies, pharmacokinetic and pharmacodynamic studies, and often clinical studies to confirm the absence of such differences [1].
How do biosimilars differ from generic drugs?
Biosimilars are for biologic drugs, which are complex molecules produced from living organisms. Generic drugs are typically for small-molecule drugs and are nearly identical to their reference products. Due to the complexity of biologics, biosimilars are not exact copies but are highly similar and have no clinically meaningful differences from the reference product [1].